Fingolimod Tablet Shows 'huge Promise'
Main Category: Multiple SclerosisArticle Date: 30 Apr 2009 - 6:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
4.11 (9 votes) |
| Healthcare Prof: |  |
2.5 (2 votes) |
New trial results presented at the American Academy of Neurology (AAN) congress and released today show the Novartis multiple sclerosis (MS) tablet FTY720 (fingolimod) to be potentially beneficial for people with relapsing-remitting MS.
The Phase III results show that 80 to 83 per cent of patients taking the pill remained free of relapses during the one-year study compared to 69 per cent of those on interferon beta-1a, a current standard in treating MS relapses.
Dr. Lee Dunster, Head of Research at the MS Society, said: "The results so far presented for fingolimod show huge promise for people with relapsing remitting MS.
"The test will be whether in ongoing trials it is shown to have a positive effect on slowing the progression of MS."
Source
MS Society
Visit our multiple sclerosis section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/148295.php>
APA
http://www.medicalnewstoday.com/releases/148295.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
